- Home
- NRIX vs CSR Comparison
NRIX vs CSR Comparison
Compare NRIX & CSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- CSR
- Stock Information
- Founded
- NRIX 2009
- CSR 1970
- Country
- NRIX United States
- CSR United States
- Employees
- NRIX N/A
- CSR N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- CSR Real Estate Investment Trusts
- Sector
- NRIX Health Care
- CSR Real Estate
- Exchange
- NRIX Nasdaq
- CSR Nasdaq
- Market Cap
- NRIX 1.3B
- CSR 1.1B
- IPO Year
- NRIX 2020
- CSR N/A
- Fundamental
- Price
- NRIX $19.83
- CSR $66.01
- Analyst Decision
- NRIX Strong Buy
- CSR Buy
- Analyst Count
- NRIX 17
- CSR 7
- Target Price
- NRIX $30.29
- CSR $71.50
- AVG Volume (30 Days)
- NRIX 988.4K
- CSR 146.2K
- Earning Date
- NRIX 02-13-2025
- CSR 10-28-2024
- Dividend Yield
- NRIX N/A
- CSR 4.54%
- EPS Growth
- NRIX N/A
- CSR N/A
- EPS
- NRIX N/A
- CSR N/A
- Revenue
- NRIX $56,424,000.00
- CSR $258,642,000.00
- Revenue This Year
- NRIX N/A
- CSR N/A
- Revenue Next Year
- NRIX $3.79
- CSR $3.55
- P/E Ratio
- NRIX N/A
- CSR N/A
- Revenue Growth
- NRIX N/A
- CSR N/A
- 52 Week Low
- NRIX $7.65
- CSR $20.10
- 52 Week High
- NRIX $29.56
- CSR $76.16
- Technical
- Relative Strength Index (RSI)
- NRIX 38.42
- CSR 31.30
- Support Level
- NRIX $19.38
- CSR $68.88
- Resistance Level
- NRIX $21.67
- CSR $69.36
- Average True Range (ATR)
- NRIX 1.34
- CSR 1.63
- MACD
- NRIX 0.00
- CSR -0.60
- Stochastic Oscillator
- NRIX 12.61
- CSR 23.31
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and they conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.